

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) Takeshi TABIRA et al.

Confirmation No.: 3468

Appl. No.: 10/560,280

Examiner: Unassigned

Filing Date: December 12, 2005

Group Art Unit: Unassigned

Title: RECOMBINANT ADENO-ASSOCIATED VIRUS VECTOR FOR
TREATMENT OF ALZHEIMER DISEASE

**STATEMENT TO SUPPORT FILING AND
SUBMISSION OF SEQUENCE LISTING**

Commission for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Mail Stop SEQUENCE


Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states upon information and belief that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter; and
2. the content of the attached paper copy, submitted in accordance with 37 C.F.R. § 1.821(c) does not include new matter.

Respectfully submitted,

Date: April 26, 2006



HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Phone: 202-912-2000
Fax: 202-912-2020

Patricia D. Granados
Reg. No. 33,683
Attorney for Applicant

Customer No. 26633

SEQUENCE LISTING

<110> Takeshi TABIRA
Hideo HARA

5

<120> A Recombinant Adeno-Associated Virus Vector for
Treatment of Alzheimer Disease

<130> 40072-0026US

10

<140> US 10/560,280

<141> 2005-12-12

<150> PCT/JP2004/008224

15

<151> 2005-06-11

<150> JP 2003-169714

<151> 2003-06-13

20

<150> JP 2003-371103

<151> 2003-10-30

<160> 19

25

<170> PatentIn Ver. 2.0

<210> 1

<211> 129

<212> DNA

30

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(129)

35

<400> 1

gat gca gaa ttc cga cat gac tca gga tat gaa gtt cat cat caa aaa 48

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

15

5

ttg gtg ttc ttt gca gaa gat gtg ggt tca aac aaa ggt gca atc att 96

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

20

25

30

10 gga ctc atg gtg ggc ggt gtt gtc ata gcg aca 129

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr

35

40

15 <210> 2

<211> 43

<212> PRT

<213> Homo sapiens

20 <400> 2

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

15

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

25

20

25

30

Gly Leu Met Val Gly Gly Val Val Ile Ala Thr

35

40

30

<210> 3

<211> 63

<212> DNA

<213> Homo sapiens

35

<220>

<221> CDS

<222> (1)..(63)

5 <400> 3

gat gca gaa ttc cga cat gac tca gga tat gaa gtt cat cat caa aaa 48

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

15

10 ttg gtg ttc ttt gca

63

Leu Val Phe Phe Ala

20

15 <210> 4

<211> 21

<212> PRT

<213> Homo sapiens

20 <400> 4

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

15

Leu Val Phe Phe Ala

25

20

<210> 5

<211> 54

30 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

35 <222> (1)..(54)

<400> 5
 atg ctg ccc ggt ttg gca ctg ctc ctg ctg gcc gcc tgg acg gct cgg 48
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 5
 gcg ctt 54
 Ala Leu

10 <210> 6
 <211> 18
 <212> PRT
 <213> Homo sapiens

15 <400> 6
 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 1 5 10 15
 Ala Leu

20

<210> 7
 <211> 197
 25 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:DNA Construct

30
 <220>
 <221> CDS
 <222> (9)..(191)

35 <220>
 <221> misc_feature

<222> (3)..(8)

<223> Xba I recognition site

<220>

5 <221> sig_peptide

<222> (9)..(62)

<400> 7

ggctctaga atg ctg ccc ggt ttg gca ctg ctc ctg ctg gcc gcc tgg acg 50
 10 Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr
 1 5 10

gct cgg gcg ctt gat gca gaa ttc cga cat gac tca gga tat gaa gtt 98
 Ala Arg Ala Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val
 15 15 20 25 30

cat cat caa aaa ttg gtg ttc ttt gca gaa gat gtg ggt tca aac aaa 146
 His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys
 35 40 45

20 ggt gca atc att gga ctc atg gtg ggc ggt gtt gtc ata gcg act 191
 Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr
 50 55 60

25 taagac 197

<210> 8

<211> 61

30 <212> PRT

<213> Artificial Sequence

<400> 8

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg
 35 1 5 10 15

Ala Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His
 20 25 30

Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala
 5 35 40 45

Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala Thr
 50 55 60

10

<210> 9

<211> 137

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence:DNA Construct

<220>

20 <221> CDS

<222> (17)..(133)

<220>

<221> misc_feature

25 <222> (3)..(10)

<223> Not I recognition site

<220>

<221> misc_feature

30 <222> (11)..(16)

<223> Xba I recognition site

<220>

<221> sig_peptide

35 <222> (17)..(70)

<400> 9

tggcggccgc tctaga atg ctg ccc ggt ttg gca ctg ctc ctg ctg gcc gcc 52

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala

1

5

10

5

tgg acg gct cgg gcg ctt gat gca gaa ttc cga cat gac tca gga tat 100

Trp Thr Ala Arg Ala Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr

15

20

25

10 gaa gtt cat cat caa aaa ttg gtg ttc ttt gct taag 137

Glu Val His His Gln Lys Leu Val Phe Phe Ala

30

35

15 <210> 10

<211> 39

<212> PRT

<213> Artificial Sequence

20 <400> 10

Met Leu Pro Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg

1

5

10

15

Ala Leu Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His

25

20

25

30

Gln Lys Leu Val Phe Phe Ala

35

30

<210> 11

<211> 27

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Primer

<400> 11

5 gatgcagaat tccgacatga ctcagga

27

<210> 12

<211> 28

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

15

<400> 12

gtcttaagtc gctatgacaa caccgccc

28

20 <210> 13

<211> 62

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:Signal Sequence

Adaptor

<400> 13

30 ggtctagaat gctgcccggg ttggcactgc tctgctggc cgctggacg gctcgggagc 60
tt 62

<210> 14

35 <211> 61

<212> DNA

<213> Artificial Sequence

$\langle 220 \rangle$

<223> Description of Artificial Sequence:Signal Sequence

5 Adaptor

<400> 14

agcgcccgag ccgtccaggc ggccagcagg agcagtgcc aaccgggcag cattctagac

60

10 c 61

<210> 15

<211> 27

15 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

20

<400> 15

ggtctagaat gctgcccggt ttggcac 27

25 <210> 16

<211> 19

<212> DNA

<213> Artificial Sequence

30 $\langle 220 \rangle$

<223> Description of Artificial Sequence:Primer

<400> 16

tggcggccgc tctagaatg 19

35

| | | |
|----|---|----|
| | <210> 17 | |
| | <211> 22 | |
| | <212> DNA | |
| | <213> Artificial Sequence | |
| 5 | <220> | |
| | <223> Description of Artificial Sequence:Primer | |
| | <400> 17 | |
| 10 | cacatcttaa gcaaagaaca cc | 22 |
| | <210> 18 | |
| | <211> 18 | |
| 15 | <212> DNA | |
| | <213> Artificial Sequence | |
| | <220> | |
| | <223> Description of Artificial Sequence:Primer | |
| 20 | <400> 18 | |
| | agtgaaccgt cagatcgc | 18 |
| 25 | <210> 19 | |
| | <211> 18 | |
| | <212> DNA | |
| | <213> Artificial Sequence | |
| 30 | <220> | |
| | <223> Description of Artificial Sequence:Primer | |
| | <400> 19 | |
| | cggatcagc tcactcaa | 18 |

| | | | | | |
|--|--|---|--|---|--|
| U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.7) 10/560,280 | | INTERNATIONAL APPLICATION NO. PCT/JP2004/008224 | | ATTORNEY'S DOCKET NUMBER 40072-0026 | |
|--|--|---|--|---|--|

21. The following fees are submitted:

| | | |
|-------------------------------------|----------------------------|----------|
| <input checked="" type="checkbox"/> | a) Basic national fee..... | \$300.00 |
| <input checked="" type="checkbox"/> | b) Examination fee | \$200.00 |
| <input checked="" type="checkbox"/> | c) Search fee..... | \$500.00 |

TOTAL OF ABOVE CALCULATIONS =

☐ Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is **\$250** for each additional 50 sheets of paper or fraction thereof.

| TOTAL SHEETS | EXTRA SHEETS | NUMBER EXTRA (of each additional 50 or fraction thereof rounded up to a whole number) | RATE |
|--------------|--------------|---|---------------|
| -100 = | 50 = | | x \$250.00 |

Surcharge of **\$130.00** for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE |
|---|------------------|--------------|--------------|
| Total claims | 18 - 20 = | 0 | x \$50.00 |
| Independent claims | 1 - 3 = | 0 | x \$200.0 |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + \$360.0 |

SUBTOTAL =

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

SUBTOTAL =

Processing fee of **\$130.00** for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

| | |
|-----------------------------|---------------|
| TOTAL NATIONAL FEE = | 130.00 |
|-----------------------------|---------------|

Fee for recording the enclose assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property

| | |
|------------------------------|---------------|
| TOTAL FEES ENCLOSED = | 130.00 |
|------------------------------|---------------|

| | |
|-------------------------------|-----------|
| Amount to be refunded: | \$ |
| Amount to be charged: | \$ |

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 08-1641 in the amount of \$130.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment
To Deposit Account No. 08-1641 A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

HELLER EHRMAN LLP
1717 Rhode Island Avenue, N.W.
Washington, D.C. 20036
Customer No.: 26633

SIGNATURE
John P. Isacson, Reg. No. 33,715

NAME
REGISTRATION NO.: 33,715

Date
February 27, 2006